Melagatran

Overview

Melagatran is a reversible, selective, orally active direct inhibitor of thrombin with a K i of 2 nM. Melagatran binds directly to the active site of thrombin , inhibiting thrombin-mediated conversion of fibrinogen to fibrin. Melagatran reduces the DNA binding activity of NF-κB and AP-1 . Melagatran reduces fibrin deposition in organs, alleviates ischemic brain damage, and reduces the size of advanced atherosclerotic lesions. Melagatran can be used in the study of cardiovascular disease (coronary thrombosis, atherosclerosis) and ischemic brain damage.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Thrombin | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > AP-1

Product Information

• Catalog No.: HY-129056
• CAS No.: 159776-70-2
• Molecular Formula: C22H31N5O4
• Molecular Weight: 429.51
• Purity: 99.31%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source